Sarepta Therapeutics (SRPT) Tops Q2 EPS by $1.32

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $2.02, $1.32 better than the analyst estimate of $0.70. Revenue for the quarter came in at $611.09 million versus the consensus estimate of $532.86 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Insurance sector reversal may favor Allstate and Progressive
• Barclays Starts Mueller Water Products (MWA) at Underweight
• Zhen Ding Technology Holding Limited (4958:TT) (HASGF) PT Raised to NT$720 at Nomura/Instinet